Published in Cancer Res on July 15, 1991
Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut (1998) 1.50
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer (1994) 1.43
High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A (1994) 1.26
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol (2005) 1.20
Isolation, cloning, and expression of a 70-kilodalton plasminogen binding protein of Borrelia burgdorferi. Infect Immun (1997) 1.10
The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J (1994) 1.09
Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol (1995) 1.03
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis (1998) 0.98
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol (2003) 0.97
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest (1993) 0.94
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS (2008) 0.90
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol (1999) 0.89
In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer (1995) 0.89
In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer (1998) 0.87
Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade. PLoS One (2012) 0.87
Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer (1993) 0.86
Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis (1997) 0.85
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol (1995) 0.82
Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene. Am J Pathol (2003) 0.82
Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer (1999) 0.82
In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. Am J Pathol (1997) 0.81
Hepatocyte growth factor/c-met signaling in regulating urokinase plasminogen activator in human stomach cancer: A potential therapeutic target for human stomach cancer. Korean J Intern Med (2006) 0.78
Tissue Specific Promoters in Colorectal Cancer. Dis Markers (2015) 0.76
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J (1993) 0.75
Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line. Biochem J (1992) 0.75
Localization of FtsI (PBP3) to the septal ring requires its membrane anchor, the Z ring, FtsA, FtsQ, and FtsL. J Bacteriol (1999) 4.87
Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol (1996) 4.02
Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature (1994) 3.97
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J (2007) 3.67
Guidelines for the management of adult lower respiratory tract infections. Eur Respir J (2005) 3.51
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect (2011) 2.99
Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol (2001) 2.80
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem (1987) 2.73
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A (1985) 2.72
Nucleotide sequence of the attenuator region of the histidine operon of Escherichia coli K-12. Proc Natl Acad Sci U S A (1978) 2.71
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem (1991) 2.68
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J (1992) 2.65
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
Use of phoA fusions to study the topology of the Escherichia coli inner membrane protein leader peptidase. J Bacteriol (1989) 2.38
Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol (1991) 2.38
Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell (1986) 2.38
Genetic analysis of the membrane insertion and topology of MalF, a cytoplasmic membrane protein of Escherichia coli. J Mol Biol (1988) 2.35
Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis (1986) 2.32
The effects of case definition in maternal screening and reporting criteria on rates of congenital syphilis. Am J Public Health (1990) 2.26
Health care abuse. CMAJ (1994) 2.22
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A (2002) 2.14
The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res (1985) 2.14
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J (2011) 2.13
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Molecular genetic analysis of membrane protein topology. Trends Genet (1988) 1.95
Application of a computerised method to measure static pressure volume curve in acute respiratory distress syndrome. Intensive Care Med (2000) 1.95
Prep1, a novel functional partner of Pbx proteins. EMBO J (1998) 1.94
The subcellular localization of PBX1 and EXD proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. Genes Dev (1999) 1.93
The novel homeoprotein Prep1 modulates Pbx-Hox protein cooperativity. EMBO J (1998) 1.93
Randomised trial of oral morphine for chronic non-cancer pain. Lancet (1996) 1.92
Genetic analysis of membrane protein topology by a sandwich gene fusion approach. Proc Natl Acad Sci U S A (1990) 1.89
Structural and functional relationships of human ferritin H and L chains deduced from cDNA clones. J Biol Chem (1985) 1.88
Socioeconomic differences among people with AIDS: results from a Multistate Surveillance Project. Am J Prev Med (1995) 1.87
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J (1990) 1.87
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene (1999) 1.81
A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J (1992) 1.81
Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci U S A (1984) 1.80
Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med (2001) 1.79
Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects. J Med Genet (2005) 1.74
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
Chlamydia pneumoniae: crossing the barriers? Eur Respir J (2004) 1.70
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res (1988) 1.70
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J (1996) 1.70
Biochemical and regulatory properties of Escherichia coli K-12 hisT mutants. J Bacteriol (1977) 1.69
Segmental expression of Hoxb2 in r4 requires two separate sites that integrate cooperative interactions between Prep1, Pbx and Hox proteins. Development (2000) 1.69
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood (2000) 1.69
Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci (1999) 1.68
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
Structure and function of epidermal growth factor-like regions in proteins. FEBS Lett (1988) 1.66
A mutant hunt for defects in membrane protein assembly yields mutations affecting the bacterial signal recognition particle and Sec machinery. Proc Natl Acad Sci U S A (2000) 1.65
Interaction between histidyl transfer ribonucleic acid and the first enzyme for histidine biosynthesis of Salmonella typhimurium. J Bacteriol (1970) 1.64
Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J (1997) 1.64
The topological analysis of integral cytoplasmic membrane proteins. J Membr Biol (1993) 1.63
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res (2000) 1.60
THE EFFECT OF MULTIPLE EMBOLI OF THE CAPILLARIES AND ARTERIOLES OF ONE LUNG. J Exp Med (1927) 1.59
FDA approved guidance conduits and wraps for peripheral nerve injury: a review of materials and efficacy. Injury (2011) 1.58
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem (1991) 1.52
An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta (2002) 1.51
Effect of subarachnoid morphine administration on extubation time after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth (2000) 1.51
Isolation of transducing bacteriophages for the histidine and isoleucine-valine operons in Escherichia coli K-12. J Bacteriol (1972) 1.50
Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem (1986) 1.49
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem (1988) 1.49
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J (1997) 1.47
Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene. Mol Psychiatry (2003) 1.47
Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol (2001) 1.46
Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol (1988) 1.44
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43
The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. Eur Respir J (2008) 1.43
Influence of dental care on children's oral health and wellbeing. Br Dent J (2013) 1.42
Identification, nucleotide sequence and expression of the regulatory region of the histidine operon of Escherichia coli K-12. Nucleic Acids Res (1981) 1.41
Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol (1989) 1.41
Interaction between the first enzyme for histidine biosynthesis and histidyl transfer ribonucleic acid. J Bacteriol (1971) 1.41
Antibiotic prescribing for discoloured sputum in acute cough/lower respiratory tract infection. Eur Respir J (2011) 1.39
Isolation of a replication origin complex from Escherichia coli. Proc Natl Acad Sci U S A (1980) 1.39
A 13-year-old female with shortness of breath and pleuritic chest pain. Eur Respir J (2006) 1.38
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene (1997) 1.37
Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene (1991) 1.37
Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis (2000) 1.36
Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester. Nucleic Acids Res (1990) 1.35
alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor. J Cell Biol (1995) 1.35
In vivo and in vitro detection of the leader RNA of the histidine operon of Escherichia coli K-12. Proc Natl Acad Sci U S A (1981) 1.34
In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol (1991) 1.33
Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J Cell Physiol (1994) 1.32
Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis (2001) 1.32
Quantitative bone mineral analysis using dual energy computed tomography. Invest Radiol (1978) 1.31
Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J (2000) 1.30
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci U S A (1989) 1.29
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem (1992) 1.29
Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res (1998) 1.28
Risk behaviors of persons with heterosexually acquired HIV infection in the United States: results of a multistate surveillance project. J Acquir Immune Defic Syndr (1994) 1.28
Characterization and proposed nomenclature of epidemic strains of MRSA in Canada. Can J Infect Dis (1999) 1.28
Adapting the HCUP QIs for hospital use: the experience in New York State. Jt Comm J Qual Improv (2001) 1.27
Direct interaction of two homeoproteins, homothorax and extradenticle, is essential for EXD nuclear localization and function. Mech Dev (2000) 1.25
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol (1991) 1.23
Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J Cell Biol (1986) 1.23
Socio-economic and behavioural risk factors for tooth loss from age 18 to 26 among participants in the Dunedin Multidisciplinary Health and Development Study. Caries Res (2000) 1.23